Obese men with prostate cancer are more likely to have aggressive tumors and to experience cancer recurrence after surgery compared with men of normal weight or those who are overweight but not obese, according to two new studies.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.